Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
The Technology Select Sector SPDR® Fund
XLK
4
Invesco Solar ETF
TAN
5
Invesco DB Commodity Index Tracking Fund
DBC
US Stock MarketDetailed Quotes
Septerna (SEPN)
- 24.840
- +1.270+5.39%
Close May 12 16:00 ET
- 25.140
- +0.300+1.21%
Post 18:33 ET
1.12BMarket Cap-31.05P/E (TTM)
25.990High23.565Low408.18KVolume24.460Open23.570Prev Close10.01MTurnover1.78%Turnover RatioLossP/E (Static)45.08MShares32.63052wk High2.96P/B568.74MFloat Cap8.86052wk Low--Dividend TTM22.90MShs Float32.630Historical High--Div Yield TTM10.29%Range %4.170Historical Low24.522Avg Price1Lot Size
SEPN Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
SEPN Orderflow
Unit: --
SEPN Orderflow Trend
IntradayDayWeekMonth
No Data
Septerna (SEPN) News
Wells Fargo Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $48
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Circle Internet Group, Inc. Class A (CRCL) and Nvidia (NVDA)
TD Cowen Maintains Septerna(SEPN.US) With Buy Rating
Septerna Reports Q1 EPS (19c), Consensus (27c)
Septerna, Inc. GAAP EPS of -$0.19 Beats by $0.25, Revenue of $26.52M Beats by $11.43M
Septerna | 10-Q: Quarterly report
Septerna (SEPN) Stock Forum
$Septerna (SEPN.US)$ 03/01/2026 - 09:45 AM
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily
Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing
Phase 2 Development Planned to Begin with Chronic Spontaneous Urticaria in the Second Half of 2026
Company to Host Conference...
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily
Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing
Phase 2 Development Planned to Begin with Chronic Spontaneous Urticaria in the Second Half of 2026
Company to Host Conference...
1
1
$Septerna (SEPN.US)$ Wow I hope people take notice the impact this deal gonna have for this company. Look at the numbers
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)